Aktis Oncology (NASDAQ:AKTS) Shares Gap Up – Still a Buy?

Shares of Aktis Oncology (NASDAQ:AKTS) gapped up prior to trading on Friday . The stock had previously closed at $19.46, but opened at $21.36. Aktis Oncology shares last traded at $21.3650, with a volume of 90,538 shares changing hands.

Wall Street Analysts Forecast Growth

Several analysts recently commented on AKTS shares. Weiss Ratings cut Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a report on Tuesday. William Blair began coverage on Aktis Oncology in a report on Wednesday, April 29th. They set an “outperform” rating on the stock. Finally, HC Wainwright increased their price target on Aktis Oncology from $33.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Aktis Oncology has an average rating of “Moderate Buy” and an average price target of $32.50.

Aktis Oncology Stock Performance

The company’s 50 day simple moving average is $19.13.

Aktis Oncology (NASDAQ:AKTS) last released its quarterly earnings data on Monday, March 30th. The technology company reported ($18.17) earnings per share for the quarter. The business had revenue of $1.87 million for the quarter. As a group, equities analysts predict that Aktis Oncology will post -1.62 EPS for the current fiscal year.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.